Download PDF
Exp Clin Endocrinol Diabetes 2003; 111(7): 443-446
DOI: 10.1055/s-2003-44292
Article

J. A. Barth Verlag in Georg Thieme Verlag Stuttgart · New York

Dose Distribution in Hydrocortisone Replacement Therapy Has a Significant Influence on Urine Free Cortisol Excretion[*]

N. Bliesener 1 , S. Steckelbroeck 1 , L. Redel 1 , D. Klingmüller 1
  • 1Department of Clinical Biochemistry, Division of Endocrinology, University of Bonn, Bonn, Germany
Further Information

Publication History

Received: December 8, 2002 First decision: February 20, 2003

Accepted: April 22, 2003

Publication Date:
13 November 2003 (online)

Also available at
    Permissions and Reprints

Abstract

We investigated the influence of dose distribution in hydrocortisone replacement therapy on urine free cortisol excretion. To this end, we measured 24-hour urine free cortisol (24-h UFC) in 13 patients with hypocortisolism. The patients took 25 mg hydrocortisone/day according to the following schedules: either a single 25 mg hydrocortisone dose at 8:00 a.m., or 15 mg hydrocortisone at 8:00 a.m. and 10 mg hydrocortisone at 2:00 p.m., or 5 mg hydrocortisone at 8:00 a.m., 10:00 a.m., 2:00 p.m., 6:00 p.m. and 10:00 p.m. 24-h UFC decreased significantly with increasing division of the daily 25 mg hydrocortisone dose. When taking 25 mg hydrocortisone in a single morning dose, the mean 24-h UFC was 649 ± 52 nmol/day (mean ± SEM). When the daily dose was divided into doses of 15 mg and 10 mg hydrocortisone, 24-h UFC was reduced by 28 % to 466 ± 39 nmol/day (p < 0.002). After division into five doses of 5 mg, 24-h UFC was reduced by 42.8 % to 371 ± 36 nmol/day (p < 0.001) compared to the single 25 mg dose. These data demonstrate that consideration of the dose distribution in hydrocortisone replacement therapy when analysing 24-h UFC is of clinical importance.

Key words

Urine free cortisol - hydrocortisone - replacement therapy - dose distribution - hypocortisolism

1 In part presented at the 46th Symposium of the “Deutsche Gesellschaft für Endokrinologie”, Göttingen, Germany, February 27 - March 2, 2002.

References

  • 1 Burch W M. Urine free-cortisol determination. A useful tool in the management of chronic hypoadrenal states.  J Am Med Assoc. 1982;  247 2002-2004
    CrossrefPubMedSearch in Google Scholar
  • 2 Esteban N V, Longhlin T, Yergey A L, Zawadzki J K, Booth J D, Winterer J C, Loriaux D L. Daily cortisol production rate in man determined by stable isotope dilution/mass spectrometry.  J Clin Endocrinol Metab. 1991;  72 39-45
    CrossrefPubMedSearch in Google Scholar
  • 3 Groves R W, Toms G C, Houghton B J, Monson J P. Corticosteroid replacement therapy: twice or thrice daily?.  J Royal Soc Med. 1988;  81 514-516
    PubMedSearch in Google Scholar
  • 4 Howlett T A. An assessment of optimal hydrocortisone replacement therapy.  Clin Endocrinol. 1997;  46 263-268
    CrossrefPubMedSearch in Google Scholar
  • 5 James V H, Few J D. Adrenocorticosteroids: chemistry, synthesis and disturbances in disease.  Clin Endocrinol Metab. 1985;  14 867-892
    PubMedSearch in Google Scholar
  • 6 Jeffcoate W. Assessment of corticosteroid replacement therapy in adults with adrenal insufficiency.  Ann Clin Biochem. 1999;  36 151-157
    PubMedSearch in Google Scholar
  • 7 Mericq M V, Cutler Jr G B. High fluid intake increases urine free cortisol excretion in normal subjects.  J Clin Endocrinol Metab. 1998;  83 682-684
    CrossrefPubMedSearch in Google Scholar
  • 8 Orth D N. The adrenal cortex. Wilson JD, Foster DW, Kronenberg HM, Larsen PR Williams Textbook of Endocrinology. Philadelphia, Pennsylvania; WB Saunders Company 1998: 517-664
    Search in Google Scholar
  • 9 Peacey S R, Guo C Y, Robinson A M, Price A, Giles M A, Eastell R, Weetman A P. Glucocorticoid replacement therapy: are patients overtreated and does it matter?.  Clin Endocrinol. 1997;  46 255-261
    CrossrefPubMedSearch in Google Scholar
  • 10 Trainer P J, McHardy K C, Harvey R D, Reid I W. Urinary free cortisol in the assessment of hydrocortisone replacement therapy.  Hormone Metab Res. 1993;  25 117-120
    PubMedSearch in Google Scholar
  • 11 Wichers M, Springer W, Bidlingmaier F, Klingmuller D. The influence of hydrocortisone substitution on the quality of life and parameters of bone metabolism in patients with secondary hypocortisolism.  Clin Endocrinol. 1999;  50 759-765
    CrossrefPubMedSearch in Google Scholar
  • 12 Zelissen P M, Croughs R J, van Rijk P P, Raymakers J A. Effect of glucocorticoid replacement therapy on bone mineral density in patients with Addison disease.  Ann Intern Med. 1994;  120 207-210
    PubMedSearch in Google Scholar

1 In part presented at the 46th Symposium of the “Deutsche Gesellschaft für Endokrinologie”, Göttingen, Germany, February 27 - March 2, 2002.

Dr. Niclaas Bliesener

Department of Clinical Biochemistry, Division of Endocrinology
University of Bonn

Sigmund-Freud-Straße 25

53105 Bonn

Germany

Phone: + 492282876513

Fax: + 49 22 82 87 50 28

Email: nbliesener@yahoo.com